aNSCLC	non-oncogene addicted advanced non-small cell lung cancer
PD-L1	programmed death-ligand 1
TMB	tumor mutation burden
IO	immunotherapy
H-TMB	high TMB
L-TMB	low TMB
S-pts	smoking patients
NS-pts	never-smoking patients
DDR	DNA damage response and repair
ECOG PS	Eastern Cooperative Oncology Group performance status score
NGS	next generation sequencing
PD	progressive disease
RECIST	Response Evaluation Criteria in Solid Tumors
CR	complete response
PR	partial response
SD	stable disease
ORR	objective response rate
bNGS	blood-based NGS
BEP	biomarker-evaluable population
OS	overall survival
PFS	progression-free survival
EGFR	epidermal growth factor receptor
ALK	anaplastic lymphoma kinase
COSMIC	Catalogue of Somatic Mutations in Cancer
Mb	megabase
bTMB	blood TMB (bTMB)
C	communities